Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$135.42

-4.67 (-3.33%)

, HALO

Halozyme

$16.63

-0.12 (-0.72%)

12:01
07/12/19
07/12
12:01
07/12/19
12:01

Halozyme announces Janssen's BLA submission for Darzalex

Halozyme Therapeutics, Inc. (HALO) announced that its collaborator Janssen Biotech, Inc. (JNJ) has submitted a Biologics License Application to the U.S. Food and Drug Administration for the subcutaneous delivery of DARZALEX for patients with multiple myeloma. "Janssen's BLA submission for subcutaneous DARZALEX represents an important development for our ENHANZE drug delivery technology business," said Dr. Helen Torley, president and chief executive officer. "We are delighted that an approval of the subcutaneous formulation may soon provide patients with multiple myeloma a new therapeutic option that offers the potential of DARZALEX with a shorter administration time."

JNJ

Johnson & Johnson

$135.42

-4.67 (-3.33%)

HALO

Halozyme

$16.63

-0.12 (-0.72%)

  • 16

    Jul

  • 09

    Sep

  • 16

    Sep

JNJ Johnson & Johnson
$135.42

-4.67 (-3.33%)

07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/11/19
JEFF
07/11/19
NO CHANGE
Target $40
JEFF
Buy
Australia implants decision a 'big positive' for Establishment, says Jefferies
After Australia's Therapeutic Goods Administration proposed to cancel or suspend use of textured breast implants, concluding that these devices are associated with a higher rate of anaplastic large cell lymphoma, or ALCL, Jefferies analyst Raj Denhoy called the decision a "big positive" for Establishment Labs (ESTA). The decision is still in the proposal stage, but Establishment is the only manufacturer with products approved in Australia that is not on the list, which proposes to ban implants from Allergan (AGN), J&J's (JNJ) Mentor and other manufacturers, according to Denhoy. He keeps a Buy rating and $40 price target on shares of Establishment Labs.
07/12/19
FBCO
07/12/19
INITIATION
Target $156
FBCO
Outperform
Johnson & Johnson assumed with an Outperform at Credit Suisse
Credit Suisse analyst Matt Miksic assumed coverage of Johnson & Johnson with an Outperform rating and $156 price target. In a research note to investors, Miksic cites key drivers to the rating, including continued growth in Immunology, driven by Stelera and Tremfya, sustainable growth in Oncology driven by Imbruvica, Darzelex and Erleada, an "attractive" pipeline of filings in the 2019-2023 timeframe with greater than$1B potential each, and "stable" growth and cash flows in Medical Devices and Consumer.
07/12/19
WELS
07/12/19
NO CHANGE
Target $29
WELS
Outperform
Australia implant ban 'excellent news' for Establishment Labs, says Wells Fargo
Wells Fargo analyst David Maris believes Australia's proposal to ban, suspend or impose strict restrictions on a number of textured implants from Allergan (AGN), Johnson & Johnson (JNJ) and other smaller manufacturers is "excellent news" for Establishment Labs Holdings (ESTA). The move by Australia's regulatory body Therapeutic Goods Administration will help solidify Establishment's reputation for safety as the company's Motiva brand is the only listed company without any restricted brands, Maris tells investors in a research note. Further, Australia is a highly regulated and developed market, so the ban could help shift market share in other geographies outside of the county as well, contends the analyst. Maris reiterates an Outperform rating on Establishment Labs with a $29 priced target. The stock closed yesterday up $1.54 to $22.44.
HALO Halozyme
$16.63

-0.12 (-0.72%)

11/27/18
JMPS
11/27/18
NO CHANGE
Target $21
JMPS
Outperform
Halozyme Phase 3 trial amendment makes sense, says JMP Securities
After Halozyme announced that it is amending the design of the Phase 3 trial evaluating PEGPH20 in front-line pancreatic cancer to make overall survival the sole primary endpoint, JMP Securities analyst Jason Butler said he thinks the change makes sense and is neutral to his thesis. While the change pushes out first results by about 6-9 months, the "outcome will be definitive," said Butler, who reiterates an Outperform rating and $21 price target on Halozyme shares.
01/11/19
WELS
01/11/19
NO CHANGE
WELS
Outperform
Halozyme undervalued relative to 'de -risked' assets, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Overweight rating on Halozyme Therapeutics following this week's update and 2019 outlook. The analyst continues to view the company as undervalued relative to its "highly de -risked" lead Enhanze assets. He sees "significant option value" to the broader Enhanze opportunity and PEGPH20 data.
02/05/19
PIPR
02/05/19
NO CHANGE
Target $161
PIPR
Overweight
Piper says argenx cusatuzumab study could enable registration if responses hold
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $161 price target on argenx (ARGX) after the company announced a collaboration agreement with Halozyme (HALO). In a research note to investors, Tenthoff says that an ongoing Phase II study of cusatuzumab, which was licensed to Janssen (JNJ) after demonstrating a 92% response rate in AML at ASH, could enable registration if responses hold. The company will host an R&D Day in NYC on May 16 to introduce ARGX-117 and also expects the company will introduce ARGX-118.
07/01/19
CANT
07/01/19
NO CHANGE
Target $27
CANT
Overweight
Halozyme price target raised to $27 from $24 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Halozyme Therapeutics to $27 from $24 after including potential future royalty revenues from Enhanze-enhanced drugs developed by partner companies. The analyst continues to view the approval and launch of the Enhanze-based products as "fueling sustainable revenue growth" through 2027, with the Darzalex program as the near-term driver. He sees "notable potential" share upside "almost irrespective" of the outcome of the HALO-301 Phase trial in pancreatic cancer later in 2019. Duncan reiterates an Overweight rating on Halozyme.

TODAY'S FREE FLY STORIES

WABC

Westamerica

$60.52

0.09 (0.15%)

11:00
07/18/19
07/18
11:00
07/18/19
11:00
Earnings
Westamerica reports Q2 EPS 73c, consensus 73c »

The company recognized no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVR

Evercore Partners

$88.51

0.725 (0.83%)

10:59
07/18/19
07/18
10:59
07/18/19
10:59
Periodicals
Evercore to lose out as Aramco reshuffles IPO roles, Reuters reports »

Evercore Partners has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 06

    Aug

MAS

Masco

$37.91

-0.71 (-1.84%)

10:55
07/18/19
07/18
10:55
07/18/19
10:55
Options
Masco put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

ADTN

Adtran

$15.25

-0.59 (-3.72%)

10:54
07/18/19
07/18
10:54
07/18/19
10:54
Earnings
Adtran sees Q3 revenue $130M-$150M, consensus $160.11M »

Sees Q3 gross margins…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

PHR

Phreesia

$0.00

(0.00%)

10:52
07/18/19
07/18
10:52
07/18/19
10:52
Syndicate
Breaking Syndicate news story on Phreesia »

Phreesia opens at $26.75,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

TEVA

Teva

$7.90

-0.21 (-2.59%)

10:50
07/18/19
07/18
10:50
07/18/19
10:50
Periodicals
Teva's sinking bond price posing insolvency threat, Haaretz says »

The decline of Teva share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

PHR

Phreesia

$0.00

(0.00%)

10:48
07/18/19
07/18
10:48
07/18/19
10:48
Syndicate
Breaking Syndicate news story on Phreesia »

Phreesia indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

GMAB

Genmab

$0.00

(0.00%)

10:47
07/18/19
07/18
10:47
07/18/19
10:47
Syndicate
Breaking Syndicate news story on Genmab »

Genmab opens at $18.25,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

10:45
07/18/19
07/18
10:45
07/18/19
10:45
General news
Oil Action: WTI crude »

Oil Action: WTI crude is…

10:45
07/18/19
07/18
10:45
07/18/19
10:45
General news
Breaking General news story  »

3-Month Bill Announcement…

10:45
07/18/19
07/18
10:45
07/18/19
10:45
General news
Breaking General news story  »

6-Month Bill Announcement…

ZBRA

Zebra Technologies

$184.79

-12.87 (-6.51%)

10:44
07/18/19
07/18
10:44
07/18/19
10:44
Downgrade
Zebra Technologies rating change at Wellington Shields »

Zebra Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

ADTN

Adtran

$15.52

-0.32 (-2.02%)

10:43
07/18/19
07/18
10:43
07/18/19
10:43
Earnings
Adtran reports preliminary Q2 adjusted EPS 14c, consensus 8c »

Reports preliminary Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

NFLX

Netflix

$324.70

-37.8 (-10.43%)

10:40
07/18/19
07/18
10:40
07/18/19
10:40
Options
Netflix selloff exceeds implied move level following earnings »

Netflix selloff exceeds…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WORK

Slack Technologies

$33.01

-0.45 (-1.34%)

10:39
07/18/19
07/18
10:39
07/18/19
10:39
Hot Stocks
Slack resets passwords for 1% of its users because of 2015 hack »

Slack published details…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHR

Phreesia

$0.00

(0.00%)

10:38
07/18/19
07/18
10:38
07/18/19
10:38
Syndicate
Breaking Syndicate news story on Phreesia »

Phreesia indicated to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

SONM

Sonim

$13.62

-0.18 (-1.30%)

10:38
07/18/19
07/18
10:38
07/18/19
10:38
Initiation
Sonim initiated at B. Riley FBR »

B. Riley FBR starts Sonim…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

NFLX

Netflix

$324.58

-37.92 (-10.46%)

, AMZN

Amazon.com

$1,983.50

-8.91 (-0.45%)

10:37
07/18/19
07/18
10:37
07/18/19
10:37
On The Fly
Analysts still see growth as Netflix slides following quarterly subscriber miss »

Shares of Netflix (NFLX)…

NFLX

Netflix

$324.58

-37.92 (-10.46%)

AMZN

Amazon.com

$1,983.50

-8.91 (-0.45%)

DIS

Disney

$141.18

-1.41 (-0.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 06

    Aug

NTAP

NetApp

$59.32

-0.03 (-0.05%)

10:35
07/18/19
07/18
10:35
07/18/19
10:35
Options
NetApp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULC

Fulcrum Therapeutics

$0.00

(0.00%)

10:31
07/18/19
07/18
10:31
07/18/19
10:31
Syndicate
Fulcrum Therapeutics indicated to open at $15.00, IPO priced at $16.00 »

Fulcrum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

10:30
07/18/19
07/18
10:30
07/18/19
10:30
General news
EIA natural gas storage change for week ending July 12 »

Gas inventories 62 Bcf…

AMK

AssetMark Financial

$0.00

(0.00%)

10:28
07/18/19
07/18
10:28
07/18/19
10:28
Syndicate
Breaking Syndicate news story on AssetMark Financial »

AssetMark Financial opens…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

GMAB

Genmab

$0.00

(0.00%)

10:25
07/18/19
07/18
10:25
07/18/19
10:25
Syndicate
Breaking Syndicate news story on Genmab »

Genmab indicated to open…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

DISH

Dish

$40.74

-0.12 (-0.29%)

10:25
07/18/19
07/18
10:25
07/18/19
10:25
Options
Dish call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
07/18/19
07/18
10:25
07/18/19
10:25
Conference/Events
SunTrust technology analysts to hold an analyst/industry conference call »

Technology Analysts…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.